RET proto-oncogene genotyping using unlabeled probes, the masking technique, and amplicon high-resolution melting analysis

Rebecca L. Margraf, Rong Mao, W Edward Jr. Highsmith, Leonard M. Holtegaard, Carl T. Wittwer

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Single bp mutations in the RET proto-oncogene can cause multiple endocrine neoplasia type 2 syndromes. The conventional approach for genotyping RET mutations is sequencing the exons. A closed-tube RET genotyping assay using a saturating DNA dye, unlabeled probes, and amplicon high-resolution melting analysis was developed. The method required two sequential polymerase chain reaction stages, a primary and secondary assay. The primary assay analyzed RET exons 10, 11, 13, 14, and 16 with a total of seven reactions using eight unlabeled probes. The primary assay genotyped wild-type exons, a common exon 13 polymorphism, and an exon 16 mutation, whereas other RET sequence variation was detected. The primary unlabeled probe data limited the possible genotypes for the detected RET sequence variation, which permitted genotyping in a secondary assay with only two to five reactions. Six probes were designed with the masking technique and masked selected sequence variations to allow unambiguous analysis of other mutations elsewhere under the probe. After this two-stage RET genotyping assay, less than 0.2% of exons tested would require sequencing for genotype. A blinded study generated from five wild type and 29 available RET sequence variation samples was 100% concordant with sequencing. Amplicon high-resolution melting analysis with unlabeled probes and the masking technique is a fast, accurate method for genotyping the >50 RET sequence variations.

Original languageEnglish (US)
Pages (from-to)184-196
Number of pages13
JournalJournal of Molecular Diagnostics
Volume9
Issue number2
DOIs
StatePublished - Apr 2007

Fingerprint

Proto-Oncogenes
Freezing
Exons
Mutation
Genotype
Multiple Endocrine Neoplasia Type 2a
Multiple Endocrine Neoplasia
Coloring Agents
Polymerase Chain Reaction
DNA

ASJC Scopus subject areas

  • Molecular Biology

Cite this

RET proto-oncogene genotyping using unlabeled probes, the masking technique, and amplicon high-resolution melting analysis. / Margraf, Rebecca L.; Mao, Rong; Highsmith, W Edward Jr.; Holtegaard, Leonard M.; Wittwer, Carl T.

In: Journal of Molecular Diagnostics, Vol. 9, No. 2, 04.2007, p. 184-196.

Research output: Contribution to journalArticle

Margraf, Rebecca L. ; Mao, Rong ; Highsmith, W Edward Jr. ; Holtegaard, Leonard M. ; Wittwer, Carl T. / RET proto-oncogene genotyping using unlabeled probes, the masking technique, and amplicon high-resolution melting analysis. In: Journal of Molecular Diagnostics. 2007 ; Vol. 9, No. 2. pp. 184-196.
@article{67256c46371149ce8a6cd6b4e5724f6e,
title = "RET proto-oncogene genotyping using unlabeled probes, the masking technique, and amplicon high-resolution melting analysis",
abstract = "Single bp mutations in the RET proto-oncogene can cause multiple endocrine neoplasia type 2 syndromes. The conventional approach for genotyping RET mutations is sequencing the exons. A closed-tube RET genotyping assay using a saturating DNA dye, unlabeled probes, and amplicon high-resolution melting analysis was developed. The method required two sequential polymerase chain reaction stages, a primary and secondary assay. The primary assay analyzed RET exons 10, 11, 13, 14, and 16 with a total of seven reactions using eight unlabeled probes. The primary assay genotyped wild-type exons, a common exon 13 polymorphism, and an exon 16 mutation, whereas other RET sequence variation was detected. The primary unlabeled probe data limited the possible genotypes for the detected RET sequence variation, which permitted genotyping in a secondary assay with only two to five reactions. Six probes were designed with the masking technique and masked selected sequence variations to allow unambiguous analysis of other mutations elsewhere under the probe. After this two-stage RET genotyping assay, less than 0.2{\%} of exons tested would require sequencing for genotype. A blinded study generated from five wild type and 29 available RET sequence variation samples was 100{\%} concordant with sequencing. Amplicon high-resolution melting analysis with unlabeled probes and the masking technique is a fast, accurate method for genotyping the >50 RET sequence variations.",
author = "Margraf, {Rebecca L.} and Rong Mao and Highsmith, {W Edward Jr.} and Holtegaard, {Leonard M.} and Wittwer, {Carl T.}",
year = "2007",
month = "4",
doi = "10.2353/jmoldx.2007.060091",
language = "English (US)",
volume = "9",
pages = "184--196",
journal = "Journal of Molecular Diagnostics",
issn = "1525-1578",
publisher = "Association of Molecular Pathology",
number = "2",

}

TY - JOUR

T1 - RET proto-oncogene genotyping using unlabeled probes, the masking technique, and amplicon high-resolution melting analysis

AU - Margraf, Rebecca L.

AU - Mao, Rong

AU - Highsmith, W Edward Jr.

AU - Holtegaard, Leonard M.

AU - Wittwer, Carl T.

PY - 2007/4

Y1 - 2007/4

N2 - Single bp mutations in the RET proto-oncogene can cause multiple endocrine neoplasia type 2 syndromes. The conventional approach for genotyping RET mutations is sequencing the exons. A closed-tube RET genotyping assay using a saturating DNA dye, unlabeled probes, and amplicon high-resolution melting analysis was developed. The method required two sequential polymerase chain reaction stages, a primary and secondary assay. The primary assay analyzed RET exons 10, 11, 13, 14, and 16 with a total of seven reactions using eight unlabeled probes. The primary assay genotyped wild-type exons, a common exon 13 polymorphism, and an exon 16 mutation, whereas other RET sequence variation was detected. The primary unlabeled probe data limited the possible genotypes for the detected RET sequence variation, which permitted genotyping in a secondary assay with only two to five reactions. Six probes were designed with the masking technique and masked selected sequence variations to allow unambiguous analysis of other mutations elsewhere under the probe. After this two-stage RET genotyping assay, less than 0.2% of exons tested would require sequencing for genotype. A blinded study generated from five wild type and 29 available RET sequence variation samples was 100% concordant with sequencing. Amplicon high-resolution melting analysis with unlabeled probes and the masking technique is a fast, accurate method for genotyping the >50 RET sequence variations.

AB - Single bp mutations in the RET proto-oncogene can cause multiple endocrine neoplasia type 2 syndromes. The conventional approach for genotyping RET mutations is sequencing the exons. A closed-tube RET genotyping assay using a saturating DNA dye, unlabeled probes, and amplicon high-resolution melting analysis was developed. The method required two sequential polymerase chain reaction stages, a primary and secondary assay. The primary assay analyzed RET exons 10, 11, 13, 14, and 16 with a total of seven reactions using eight unlabeled probes. The primary assay genotyped wild-type exons, a common exon 13 polymorphism, and an exon 16 mutation, whereas other RET sequence variation was detected. The primary unlabeled probe data limited the possible genotypes for the detected RET sequence variation, which permitted genotyping in a secondary assay with only two to five reactions. Six probes were designed with the masking technique and masked selected sequence variations to allow unambiguous analysis of other mutations elsewhere under the probe. After this two-stage RET genotyping assay, less than 0.2% of exons tested would require sequencing for genotype. A blinded study generated from five wild type and 29 available RET sequence variation samples was 100% concordant with sequencing. Amplicon high-resolution melting analysis with unlabeled probes and the masking technique is a fast, accurate method for genotyping the >50 RET sequence variations.

UR - http://www.scopus.com/inward/record.url?scp=34247874785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247874785&partnerID=8YFLogxK

U2 - 10.2353/jmoldx.2007.060091

DO - 10.2353/jmoldx.2007.060091

M3 - Article

C2 - 17384210

AN - SCOPUS:34247874785

VL - 9

SP - 184

EP - 196

JO - Journal of Molecular Diagnostics

JF - Journal of Molecular Diagnostics

SN - 1525-1578

IS - 2

ER -